Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
SiTime Q1 2026 Earnings Call - AI Inference Drives 88% Revenue Surge to $113.6M
SiTime delivered a blistering Q1 2026, with revenue surging 88% year-over-year to $113.6 million and non-GAAP EPS jumping five-fold to $1.44. The growth is being pulled by the Communications, Enterpri...
- Revenue surged 88% year-over-year to $113.6 million in Q1 2026, significantly beating prior expectations and validating management's aggressive growth trajectory.
- Non-GAAP EPS jumped five-fold to $1.44, up from $0.26 in Q1 2025, reflecting both top-line expansion and sharp operating leverage.
- CED revenue grew 158% year-over-year to $75.7 million, now representing 66.6% of total revenue and marking the eighth straight quarter of triple-digit growth.
- +7 more takeaways
Brightstar Lottery Q1 2026 Earnings Call - Strong Margin Expansion and iLottery Momentum Offset U.S. Retail Headwinds
Brightstar Lottery delivered a resilient first quarter in 2026, with reported revenue of EUR 590 million rising 1% and adjusted EBITDA surging 15% as the company’s Optima efficiency program and strong...
- Reported revenue of EUR 590 million increased 1% year-over-year, while constant-currency growth excluding service revenue amortization reached 3%, driven by strong performance in Italy and a favorable U.S. mix.
- Adjusted EBITDA grew 15% as reported and 5% at constant currency, reflecting the effectiveness of the Optima efficiency program and high flow-through of Italian same-store sales growth, though upfront license fee amortization artificially boosted the reported margin.
- Global iLottery wagers surged 30% in the first quarter, with U.S. wagers climbing 36% and Italian wagers increasing 27%, underscoring the company’s leadership in digital lottery platforms and content.
- +7 more takeaways
D-Wave Systems Inc Q1 2026 Earnings Call - Bookings Surge 2,000% on Quantum Circuits Acquisition and Dual-Rail Roadmap
D-Wave Systems reported a record first quarter with bookings of $33.4 million, a nearly 2,000% year-over-year increase driven by a $20 million system sale to Florida Atlantic University and the indust...
- Bookings surged 1,994% year-over-year to $33.4 million, with a $20 million system sale to Florida Atlantic University and a $10 million enterprise license deal driving the increase.
- Revenue fell 81% to $2.9 million due to the recognition of a $12.6 million system sale in the prior year period, but commercial revenue now represents 73% of the total.
- Remaining performance obligations (backlog) jumped 563% to $42.4 million, with 54% expected to be recognized as revenue within the next 12 months.
- +7 more takeaways
Satellogic Q1 2026 Earnings Call - First-Quarter Positive Operating Cash Flow Signals Commercial Inflection
Satellogic delivered a structural inflection in Q1 2026, marking its first quarter of positive operating cash flow while revenue surged 80% year-over-year to $6.1 million. The company’s vertically int...
- Satellogic reported first-quarter revenue of $6.1 million, an 80% year-over-year increase, driven by $1.6 million in growth from imagery orders across new and existing data and analytics customers.
- The company achieved its first-ever positive net cash from operating activities, generating $0.2 million and narrowing its adjusted EBITDA loss by 32% to $4.2 million, highlighting immediate operating leverage.
- Asia-Pacific revenue expanded more than eightfold to $3 million, led by sovereign and commercial demand in Australia and Malaysia, underscoring rapid international diversification.
- +7 more takeaways
3D Systems Q1 2026 Earnings Call - Healthcare Revenue Surpasses Industrial as Denture Launch Gains Traction
3D Systems delivered a resilient first quarter, with revenue climbing 11% to $95.5 million as the additive manufacturing sector finally stumbles out of a multi-year slump. Healthcare Solutions overtoo...
- Revenue grew 11% year-over-year to $95.5 million, marking a solid return to growth after a prolonged downturn.
- Healthcare Solutions revenue surged 21% to $50.1 million, surpassing Industrial Solutions as the company’s largest segment.
- Industrial Solutions revenue rose 1.6% to $45.4 million, with aerospace and defense driving over 20% growth.
- +7 more takeaways
Vir Biotechnology Q1 2026 Earnings Call - Astellas Partnership Closes, HDV Data Shows 88% Viral Clearance
Vir Biotechnology closed its landmark $1.7 billion global collaboration with Astellas for VIR-5500, a PRO-XTEN dual-masked PSMA-targeted T-cell engager, bringing an initial $315 million in proceeds an...
- Astellas collaboration for VIR-5500 officially closed on April 15, 2026, delivering an immediate $315 million in cash proceeds and shifting global development costs to a 40/60 split in Vir's favor.
- VIR-5500 phase I data demonstrated a favorable safety profile with no dose-limiting toxicities and grade 1 cytokine release syndrome only at doses of 3,000 mcg/kg and above, supporting outpatient administration potential.
- Deep PSA and RECIST responses were observed in heavily pretreated mCRPC patients, including those with liver metastasis and prior radioligand therapy failure, with durability extending up to 12 months in select cases.
- +7 more takeaways
NeuroOne Medical Technologies Corporation Q2 Fiscal 2026 Earnings Call - OneRF Revenue Surges 72% as Management Pivots to International Expansion and New Product Rollouts
NeuroOne’s second quarter fiscal 2026 results paint a picture of a company in transition, balancing rapid growth in its core brain ablation business with the slow burn of developing new therapeutic pl...
- Product revenue grew 72% year over year to $2.4 million in Q2 fiscal 2026, driven by strong sales of the OneRF brain ablation system.
- The company lost $3 million in license revenue from its Zimmer Biomet partnership, a significant drop from the prior year that highlights the shift to direct product sales.
- Cash and cash equivalents declined sharply to $2.8 million as of March 31, 2026, down from $6.6 million six months earlier, raising questions about the timeline for a potential capital raise.
- +7 more takeaways
Achieve Life Sciences Q1 2026 Earnings Call - Cytisinicline NDA Resubmission Pushed to Q4 2026 Following Manufacturing CRL, $180M Financing Secured
Achieve Life Sciences navigated a pivotal quarter marked by a leadership transition and a manufacturing setback that delays its NDA resubmission for cytisinicline, a potential first-in-class smoking c...
- Achieve Life Sciences closed a transformative $180 million private placement, plus up to $174 million from milestone-based warrants exercisable around FDA approval, significantly strengthening its balance sheet for commercialization.
- CEO Dr. Andrew Goldberg emphasized a strategy of independent commercialization with a dedicated field force, leveraging new hires from Verona Pharma’s successful Ohtuvayre launch to drive execution.
- The company expects to receive a Complete Response Letter (CRL) from the FDA by its June 20, 2026 PDUFA date, primarily due to CGMP observations at a third-party manufacturer unrelated to the drug product itself.
- +7 more takeaways
Eco Wave Power Q1 2026 Earnings Call - Wave Energy Positioned for AI Infrastructure Boom
Eco Wave Power reported a tighter operating loss of $682,000 in Q1 2026, down from $765,000 a year prior, driven by disciplined cost cuts across R&D, sales, and administration. The company holds $5.3 ...
- Operating expenses fell 11% year-over-year to $682,000, with R&D dropping to $140,000 from $181,000 and G&A down to $499,000 from $539,000.
- Operating loss improved to $682,000 from $765,000 in Q1 2025, though net loss widened to $695,000 due to foreign exchange fluctuations.
- The company maintains $5.3 million in total liquidity as of March 31, 2026, ensuring runway for ongoing operations and project development.
- +7 more takeaways
WM Technology Q1 2026 Earnings Call - Strategic Delisting and Cannabis Rescheduling Unlocks Next Phase
WM Technology reported Q1 2026 revenue of $43.6 million, down 2% year-over-year but in line with expectations. The company navigated a difficult operating environment marked by price compression, elev...
- Revenue for Q1 2026 was $43.6 million, down 2% year-over-year but up 1% sequentially, aligning with management expectations.
- Average monthly paying clients declined 4% year-over-year to approximately 4,983, primarily due to churn in mature markets like California, Michigan, and Colorado.
- Client churn was driven by financial stress, price compression, and non-payment issues among operators in saturated markets.
- +7 more takeaways